At Evonetix we are reimagining biology by developing a radically different approach to gene synthesis – a highly parallel desktop platform ...
Location: United Kingdom, England, Cambridge
Employees: 51-200
Total raised: $66.6M
Founded date: 2015
Investors 6
| Date | Name | Website |
| - | Foresite C... | foresiteca... |
| - | DCVC | dcvc.com/ |
| - | Molten Ven... | moltenvent... |
| - | Civilizati... | civilizati... |
| - | Start Capi... | start-capi... |
| - | Draper Esp... | draperespr... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 08.02.2023 | Series B | $24.3M | Foresite C... |
| 02.03.2020 | Series B | $30M | Foresite C... |
| 30.01.2018 | Series A | $12.3M | DCVC |
Mentions in press and media 23
| Date | Title | Description |
| 08.02.2023 | Evonetix Raises Additional $24M in Series B Funding | Evonetix, a Cambridge, UK-based synthetic biology company bringing semiconductor technology to DNA synthesis, raised additional $24M in Series B, extending the total raised in the round to over USD $54M. The round was led by Foresite Capita... |
| 07.02.2023 | UK’s Evonetix extends Series B with €22.3M to commercialise DNA synthesis platform | Cambridge-based Evonetix, a synthetic biology company that brings semiconductor technology to DNA synthesis, announced on Tuesday, February 7, that it has raised an additional $24M (approximately €22.36M) to bring its total Series B funding... |
| 07.02.2023 | Evonetix lands £20m for DNA synthesis semiconductors | Deeptech startup Evonetix has landed $24m (£20m) in an extension investment round led by Foresite Capital, which brings its Series B total to $54m (£45m). Cambridge-based Evonetix conducts DNA synthesising by using a computer chip that mana... |
| 07.02.2023 | Evonetix closes $24 million USD (£20 million) financing | Oversubscribed round led by Foresite Capital Funding will enable development of DNA synthesis chip technology to commercial scale EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, t... |
| 07.02.2023 | Bringing semiconductor tech to DNA synthesis, Evonetix secures £20 million | Cambridge-based spin-out company Evonetix has raised £20 million in a Series B funding round that’s aimed at helping the company scale up the commercialisation of its DNA synthesis chip technology. The round was led by existing investor For... |
| 23.09.2021 | Evonetix granted patent for DNA data storage and retrieval method | Evonetix granted patent for DNA data storage and retrieval method 23-09-2021 Evonetix Ltd, the synthetic biology company developing a desktop platform for scalable, high-fidelity and rapid gene synthesis, announced it has been granted paten... |
| 01.04.2021 | Cutting loose from Merck, Mike Nally is 'running toward a great opportunity'; Novartis partnership in hand, BeiGene promotes Julia Wang to CFO | When Mike Nally was an undergrad at Middlebury College in Vermont, he thought investment banking and finance was his “path to salvation.” He graduated in 1998 with his bachelor’s in economics, then took a job at Donald... |
| 18.09.2020 | Business Weekly Awards 2020 | Frontier Developments named Business of the Year Article by Tony Quested | Business Weekly Frontier Developments, Cambridge’s world-leading video games developer is today unveiled as Business of the Year in the toughest competition in 30 ye... |
| 23.05.2020 | Mike Kamdar, The Future Of DNA Writing, And The Business Of Biology | With a new way to write DNA, Mike Kamdar and his team at Molecular Assemblies are poised to disrupt just about any industry you can imagine. |
| 12.03.2020 | Cofinitive shortlisted in 30th Anniversary Business Weekly Awards | Cofinitive shortlisted in 30th Anniversary Business Weekly Awards 12-03-2020 Cofinitive are delighted to announce that they have been shortlisted in the upcoming Business Weekly Awards. The shortlist has listed us as “a growing team of comm... |
Show more